Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Not Recruiting

Trial ID: NCT02567409


This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin and gemcitabine hydrochloride work better alone or with berzosertib in treating patients with urothelial cancer.

Official Title

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Patients must have histologically or cytologically confirmed metastatic urothelial
   carcinoma; urothelial cancer derived from the bladder, ureter or upper tract is

   - Patients must have measurable disease, defined as at least one lesion that can be
   accurately measured in at least one dimension (longest diameter to be recorded for
   non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with
   conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT)
   scan, magnetic resonance imaging (MRI), or calipers by clinical exam

   - Patients must have access to archival tumor tissue for proposed correlative studies;
   these may be derived from transurethral resection of bladder tumors (TURBT),
   cystectomy, or biopsy; if archival tissue is not available for proposed correlatives,
   patients may be enrolled at the discretion of the study principal investigator (PI)

   - No prior cytotoxic chemotherapy for metastatic disease; prior immunotherapy is

   - At least 12 months have elapsed since platinum-based peri-operative treatment

   - Karnofsky >= 70% (Eastern Cooperative Oncology Group [ECOG] performance status 0-1)

   - Life expectancy of greater than 3 months

   - Leukocytes >= 3,000/mcL

   - Absolute neutrophil count >= 1,500/mcL

   - Platelets >= 100,000/mcL

   - Total bilirubin within institutional upper limit of normal

   - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
   [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
   =< 2.5 x institutional upper limit of normal

   - Creatinine clearance >= 50 mL/min by either measured (using the Cockcroft-Gault,
   Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology
   [CKD-EPI] formula) or calculated clearance (i.e. glomerular filtration rate [GFR])

   - The effects of M6620 (VX-970) on the developing human fetus are unknown; for this
   reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic
   agents used in this trial may have teratogenic potential, women of child-bearing
   potential and men must agree to use adequate contraception (hormonal or barrier method
   of birth control; abstinence) prior to study entry and for the duration of study
   participation; should a woman become pregnant or suspect she is pregnant while she or
   her partner is participating in this study, she should inform her treating physician
   immediately; men treated or enrolled on this protocol must also agree to use adequate
   contraception prior to the study, for the duration of study participation, and 6
   months after completion of M6620 (VX-970) administration

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Radiotherapy within 4 weeks of protocol therapy

   - Patients who are receiving any other investigational agents

   - History of allergic reactions attributed to compounds of similar chemical or biologic
   composition to M6620 (VX970), cisplatin, or gemcitabine

   - M6620 (VX-970) is primarily metabolized by CYP3A4; therefore, concomitant
   administration with strong inhibitors or inducers of CYP3A4 should be avoided; because
   the lists of these agents are constantly changing, it is important to regularly
   consult a frequently-updated medical reference for a list of drugs to avoid or
   minimize use of; Patient Drug Information Handout and Wallet Card should be provided
   to patients; as part of the enrollment/informed consent procedures, the patient will
   be counseled on the risk of interactions with other agents, and what to do if new
   medications need to be prescribed or if the patient is considering a new
   over-the-counter medicine or herbal product

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, or psychiatric illness/social situations that would limit compliance with
   study requirements

   - Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage
   response (DDR) inhibitor may have the potential for teratogenic or abortifacient
   effects; because there is an unknown but potential risk for adverse events in nursing
   infants secondary to treatment of the mother with M6620 (VX-970), breastfeeding should
   be discontinued if the mother is treated with M6620 (VX-970); these potential risks
   may also apply to other agents used in this study

   - Patients with >= grade 2 neuropathy


drug: Cisplatin

drug: Gemcitabine Hydrochloride

drug: Berzosertib

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts